ArticleCancer cell2022
A roadmap for driving CAR T cells toward the oncogenic immunopeptidome.
Article in Cancer cell, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells.Molecular oncology · 2025Review
- Immunopeptidomics in the cancer immunotherapy era.Exploration of targeted anti-tumor therapy · 2024Review
- Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy.The Journal of experimental medicine · 2023Article
- Unlocking the potential of microfluidics in mass spectrometry-based immunopeptidomics for tumor antigen discovery.Cell reports methods · 2023Review
- Advancing CAR T cell therapy through the use of multidimensional omics data.Nature reviews. Clinical oncology · 2023Review
- Review
- CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.Frontiers in immunology · 2022Article
Corrections and comments
- Comment on
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A critical barrier to CAR T cell therapy is the paucity of target antigens that are broadly and stably expressed exclusively in tumors. In their comprehensive multi-omics and pre-clinical study, Yarmarkovich et al. provide proof of principle for the development and efficacy of peptide centric (PC)-CARs targeting the oncogenic immunopeptidome of neuroblastoma.
Indexed as
Identifiers
35016027What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.